Structural basis for chemical inhibition of human blood coagulation factor Xa.

Factor Xa, the converting enzyme of prothrombin to thrombin, has emerged as an alternative (to thrombin) target for drug discovery for thromboembolic diseases. An inhibitor has been synthesized and the crystal structure of the complex between Des[1-44] factor Xa and the inhibitor has been determined by crystallographic methods in two different crystal forms to 2.3- and 2.4-A resolution. The racemic mixture of inhibitor FX-2212, (2RS)-(3'-amidino-3-biphenylyl)-5-(4-pyridylamino)pentanoic acid, inhibits factor Xa activity by 50% at 272 nM in vitro. The S-isomer of FX-2212 (FX-2212a) was found to bind to the active site of factor Xa in both crystal forms. The biphenylamidine of FX-2212a occupies the S1-pocket, and the pyridine ring makes hydrophobic interactions with the factor Xa aryl-binding site. Several water molecules meditate inhibitor binding to residues in the active site. In contrast to the earlier crystal structures of factor Xa, such as those of apo-Des[1-45] factor Xa and Des[1-44] factor Xa in complex with a naphthyl inhibitor DX-9065a, two epidermal growth factor-like domains of factor Xa are well ordered in both our crystal forms as well as the region between the two domains, which recently was found to be the binding site of the effector cell protease receptor-1. This structure provides a basis for designing next generation inhibitors of factor Xa.

[1]  H Brandstetter,et al.  The X-ray crystal structure of thrombin in complex with N alpha-2-naphthylsulfonyl-L-3-amidino-phenylalanyl-4-methylpiperidide: the beneficial effect of filling out an empty cavity. , 1995, Journal of enzyme inhibition.

[2]  D. Altieri.  Proteases and protease receptors in modulation of leukocyte effector functions , 1995, Journal of leukocyte biology.

[3]  K. High,et al.  Activation-dependent Exposure of the Inter-EGF Sequence Leu83-Leu88 in Factor Xa Mediates Ligand Binding to Effector Cell Protease Receptor-1* , 1997, The Journal of Biological Chemistry.

[4]  H Brandstetter,et al.  Enzyme flexibility, solvent and 'weak' interactions characterize thrombin-ligand interactions: implications for drug design. , 1996, Structure.

[5]  J. Trewhella,et al.  The relative orientation of Gla and EGF domains in coagulation factor X is altered by Ca2+ binding to the first EGF domain. A combined NMR-small angle X-ray scattering study. , 1996, Biochemistry.

[6]  C. Roitsch,et al.  Inhibition by Recombinant Hirudins of Experimental Venous Thrombosis and Disseminated Intravascular Coagulation Induced by Tissue Factor in Rats , 1990, Thrombosis and Haemostasis.

[7]  T. Edgington,et al.  Effector Cell Protease Receptor-1 Is a Vascular Receptor for Coagulation Factor Xa* , 1996, The Journal of Biological Chemistry.

[8]  D. Banner,et al.  Crystallographic analysis at 3.0-A resolution of the binding to human thrombin of four active site-directed inhibitors. , 1994, The Journal of biological chemistry.

[9]  S Foundling,et al.  The 2.8 A crystal structure of Gla‐domainless activated protein C. , 1996, The EMBO journal.

[10]  J. Navaza,et al.  AMoRe: an automated package for molecular replacement , 1994 .

[11]  D. Altieri,et al.  Molecular cloning of effector cell protease receptor-1, a novel cell surface receptor for the protease factor Xa. , 1994, Journal of Biological Chemistry.

[12]  Y. Konishi,et al.  Crystal structure of a peptidyl pyridinium methyl ketone inhibitor with thrombin. , 1995, Biochemistry.

[13]  H Brandstetter,et al.  X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  C. Ehrhardt,et al.  Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile. , 1993, Trends in pharmacological sciences.

[15]  K Fujikawa,et al.  The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.

[16]  A T Brünger,et al.  Slow-cooling protocols for crystallographic refinement by simulated annealing. , 1990, Acta crystallographica. Section A, Foundations of crystallography.

[17]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[18]  M. Ullner,et al.  How an epidermal growth factor (EGF)-like domain binds calcium. High resolution NMR structure of the calcium form of the NH2-terminal EGF-like domain in coagulation factor X. , 1994, The Journal of biological chemistry.

[19]  D W Banner,et al.  Molecular recognition at the thrombin active site: structure-based design and synthesis of potent and selective thrombin inhibitors and the X-ray crystal structures of two thrombin-inhibitor complexes. , 1997, Chemistry & biology.

[20]  S. Katakura,et al.  Dibasic (amidinoaryl)propanoic acid derivatives as novel blood coagulation factor Xa inhibitors. , 1994, Journal of medicinal chemistry.

[21]  C A Kettner,et al.  Structure-based understanding of ligand affinity using human thrombin as a model system. , 1996, Biochemistry.

[22]  C. Esmon,et al.  Comparison of coagulation factor Xa and des-(1-44)factor Xa in the assembly of prothrombinase. , 1984, The Journal of biological chemistry.

[23]  J. Herbert,et al.  DX 9065A a novel, synthetic, selective and orally active inhibitor of factor Xa: in vitro and in vivo studies. , 1996, The Journal of pharmacology and experimental therapeutics.

[24]  Lydia Tabernero,et al.  Crystallographic determination of the structures of human α‐thrombin complexed with BMS‐186282 and BMS‐189090 , 1996 .

[25]  M. Dioszegi,et al.  Highly active and selective anticoagulants: D-Phe-Pro-Arg-H, a free tripeptide aldehyde prone to spontaneous inactivation, and its stable N-methyl derivative, D-MePhe-Pro-Arg-H. , 1990, Journal of medicinal chemistry.

[26]  David W. Banner,et al.  The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor , 1996, Nature.

[27]  H. Ishihara,et al.  DX-9065a, a New Synthetic, Potent Anticoagulant and Selective Inhibitor for Factor Xa , 1994, Thrombosis and Haemostasis.

[28]  J. Stürzebecher,et al.  Synthetic low-molecular weight thrombin inhibitors: the ideal antithrombotic drug? An introduction. , 1995, Journal of enzyme inhibition.

[29]  H Brandstetter,et al.  Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics. , 1992, Journal of molecular biology.

[30]  R. Huber,et al.  Structure of human des(1-45) factor Xa at 2.2 A resolution. , 1993, Journal of molecular biology.

[31]  D. Altieri,et al.  Factor Xa as an interface between coagulation and inflammation. Molecular mimicry of factor Xa association with effector cell protease receptor-1 induces acute inflammation in vivo. , 1997, The Journal of clinical investigation.

[32]  C. Adida,et al.  Effector Cell Protease Receptor-1, a Platelet Activation-dependent Membrane Protein, Regulates Prothrombinase-catalyzed Thrombin Generation* , 1997, The Journal of Biological Chemistry.

[33]  M. Karplus,et al.  Crystallographic R Factor Refinement by Molecular Dynamics , 1987, Science.

[34]  T. Morita,et al.  Preparation and properties of derivatives of bovine factor X and factor Xa from which the gamma-carboxyglutamic acid containing domain has been removed. , 1986, The Journal of biological chemistry.

[35]  J. D. Frank,et al.  Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. , 1992, The Journal of pharmacology and experimental therapeutics.

[36]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[37]  M. Hussain,et al.  Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration in rats , 1991, Peptides.

[38]  J. A. Malikayil,et al.  Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety. , 1997, Biochemistry.

[39]  A. Brunger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures. , 1992 .

[40]  J H Matthews,et al.  Crystal structures of thrombin with thiazole-containing inhibitors: probes of the S1' binding site. , 1996, Biophysical journal.

[41]  Y. Konishi,et al.  Crystal structure of two new bifunctional nonsubstrate type thrombin inhibitors complexed with human α‐thrombin , 1996, Protein science : a publication of the Protein Society.

[42]  Robert Huber,et al.  X-ray Structure of Active Site-inhibited Clotting Factor Xa , 1996, The Journal of Biological Chemistry.

[43]  T. Drakenberg,et al.  Three-dimensional structure of the apo form of the N-terminal EGF-like module of blood coagulation factor X as determined by NMR spectroscopy and simulated folding. , 1992, Biochemistry.

[44]  Y Li,et al.  Crystal structure of human alpha-thrombin complexed with hirugen and p-amidinophenylpyruvate at 1.6 A resolution. , 1995, Archives of biochemistry and biophysics.

[45]  Sung-Hou Kim,et al.  Sparse matrix sampling: a screening method for crystallization of proteins , 1991 .